Swei

Quick links to important sections

Swei

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Swei

Property Description
Active Ingredients Aluminum Hydroxide, Homatropine
Form Tablet, Oral Suspension
Pharmacological Class Antacid-Anticholinergic Combination
General Purpose Symptomatic relief of acid and spasm-related digestive discomfort
Origin Synthetic and Inorganic Compound

What Type of Medicine is Swei? (Identity and Classification)

Swei is a combination pharmaceutical preparation classified as an Antacid-Anticholinergic Combination, designed to provide a dual therapeutic action. This means the medication targets symptoms arising from both excessive stomach acid and involuntary muscle spasms in the digestive tract. It is prepared for Oral Administration and is typically supplied in solid tablet or liquid oral suspension forms. The dual classification is clinically recognized for addressing both acidity and functional disturbances concurrently.


Composition: Aluminum Hydroxide and Homatropine Explained

Swei is composed of two distinct active ingredients: the inorganic compound Aluminum Hydroxide and the synthetic alkaloid Homatropine. Aluminum Hydroxide is the rapid-acting component, primarily functioning through proton binding to neutralize hydrochloric acid and raise the gastric pH. Homatropine acts as a Cholinergic Muscarinic Antagonist, working to reduce nerve signals that trigger acid secretion and involuntary gastrointestinal movement.

This specific combination is supported by pharmacological studies confirming the complementary roles of the components. The inclusion of Homatropine is intended to provide an anti-spasmodic benefit, addressing painful cramping in addition to the burning sensation caused by high acidity.


What is the General Purpose of Swei?

The general purpose of Swei is to provide effective symptomatic relief for discomfort arising from acid-related gastrointestinal conditions. A typical use scenario involves relieving acute, concurrent symptoms like heartburn accompanied by a sensation of stomach cramping or tightness. The therapeutic benefit is achieved by combining the immediate action of acid neutralization with the longer-acting effect of smooth muscle relaxation and reduced secretion, thereby addressing the two most common sources of acute digestive distress.

What side effects are possible with Swei?

Official Adverse Reactions and Safety Profile

The safety profile for this Antacid-Anticholinergic Combination is classified based on the documented effects of its two active ingredients, addressing both frequency and the organ systems involved, as reported in regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are generally associated with the components' core pharmacological effects:

  • Common: Adverse effects frequently reported include constipation (linked to the aluminum component), dry mouth, and blurred vision (common anticholinergic effects of Homatropine). Other common effects may include nausea, vomiting, dizziness, and headache.
  • Uncommon/Rare: Less frequently reported effects include tachycardia (increased heart rate) and urinary retention. Hypersensitivity reactions (e.g., rash) are classified as rare.

Clinically Significant Safety Considerations

Official labeling documents specific constraints and risks, particularly related to the duration of use or pre-existing conditions:

  • Long-Term Exposure: Prolonged use of the aluminum component is associated with the risk of Hypophosphatemia (low phosphate levels) and, in individuals with impaired kidney function, the potential for aluminum accumulation.
  • Special Populations: Older adults may have increased sensitivity to anticholinergic effects, heightening the risk of effects like urinary retention. Pediatric use is generally not recommended or requires explicit guidance.
  • Safety Restrictions: The medicine is strictly contraindicated in patients with conditions such as narrow-angle glaucoma or prostatic hypertrophy, as the anticholinergic component can exacerbate these states. Furthermore, the aluminum component may reduce the absorption of other orally administered medications.

This framework ensures that the full spectrum of potential adverse events and usage limitations is communicated in a neutral, regulatory-aligned manner.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Swei is formally documented by regulatory authorities as a situation that requires immediate emergency medical attention. Suspected overdose requires an immediate call to the Poison Help line or emergency services due to the potential for severe, life-threatening outcomes officially documented in prescribing information.

Documented Manifestations and Severe Outcomes

Overdose may present with acute gastrointestinal symptoms including severe constipation, abdominal pain, and vomiting. Systemic toxicity from the antacid component may lead to metabolic changes such as Hyperaluminemia and Hypophosphatemia, with an officially documented risk of Acute Homatropine Intoxication from the anticholinergic component.

Severe consequences listed in regulatory labeling include Intestinal obstruction or ileus, alongside serious Central Nervous System effects. These CNS effects, such as Encephalopathy, confusion, seizures, and dementia, are associated with chronic high-dose exposure or accumulation, particularly in vulnerable populations.

Mandated Emergency Actions and Supportive Measures

No specific antidote for either active ingredient is explicitly documented in the official prescribing information. Management is supportive and dictated by the documented manifestations. For patients with existing renal impairment, there is an increased risk of severe systemic toxicity, often requiring interventions such as Haemodialysis or peritoneal dialysis as explicitly outlined in regulatory guidelines. The elderly population is noted to have an increased risk of complications like intestinal obstruction.

Therapeutic Uses of Swei

What Swei Treats: Main Uses and Benefits

The therapeutic areas for this Antacid-Anticholinergic Combination are well-established, with the combination of the two types of ingredients used to support symptom management in specific gastrointestinal conditions. The antispasmodic component may be used alongside antacids in the symptomatic management of peptic ulcers and related intestinal issues to address symptoms of increased physiological or muscular activity.

The medication is relevant for easing symptom clusters that may become intense or disruptive where both heartburn and stomach cramping occur simultaneously. It is commonly used across conditions presenting with acute episodes like Gastritis, Esophagitis, Peptic Ulcer Disease, and Gastroesophageal Reflux Disease (GERD). Applied in scenarios where additional management of discomfort is required, the combination contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

“The primary goal is providing supportive relief when symptoms interfere with routine activities.”

Quick Fact: Primary Symptom Focus: Concurrent Burning and Spasms (Used for Dual Symptom Management).

Regulatory References

  1. NIH-supported drug information on Homatropine methylbromide

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Swei

This eligibility profile is defined by government regulatory documents for the active components Aluminum Hydroxide and Homatropine, detailing who is permitted to use the medicine and who is formally excluded.


Eligibility Scope

Classification Population or Condition
Populations Allowed Adults and adolescents (typically 12 years of age and older).
Contraindicated Known Hypersensitivity to any component.
Contraindicated Severe Renal Impairment or Chronic Kidney Failure.
Contraindicated Narrow-Angle Glaucoma or a predisposition to it.
Contraindicated Gastrointestinal Obstruction (including paralytic ileus).
Not Recommended Children under 12 years (use not established).
Not Recommended Pregnant or Lactating individuals.
Use with Caution Older Adults (due to increased anticholinergic sensitivity).
Use with Caution Conditions such as Obstructive Uropathy (e.g., prostatic hypertrophy).

Eligibility Classifications (High-Level)

Category Statement
Severity Classification Contraindicated, Not Recommended, Use with Caution, or Not Established.
Official Eligibility Statements Use is defined by explicit exclusions related to organ function and pre-existing conditions that are susceptible to anticholinergic effects or aluminum accumulation.

Connection to the overall eligibility profile: The official regulatory structure dictates that eligibility is constrained by age, physiological status, and specific comorbidities, ensuring the medicine is not used by populations who face an officially recognized, unacceptable risk, particularly concerning anticholinergic effects and aluminum clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Swei is defined by two primary mechanisms of interaction documented in government labeling. These mechanisms establish restrictions on co-administration with other substances.

Pharmacokinetic Absorption Interference

The Aluminum Hydroxide component of Swei can significantly reduce the systemic exposure (plasma levels) of co-administered oral medicines. This pharmacokinetic interaction results from drug binding (chelation) and an increase in gastric pH.

Affected Substance Categories:

  • Antibiotics (Quinolones, Tetracyclines)
  • Antivirals (specific acid-sensitive agents)
  • Iron Salts and Mineral Supplements

Administration Constraint: The regulatory label requires a mandatory administration separation for interacting oral drugs. These medicines must be taken at least 2 hours apart from Swei to ensure adequate absorption and exposure, as documented for agents such as Gabapentin.

Pharmacodynamic Additive Effects

The Homatropine component contributes to additive pharmacodynamic interactions with other substances.

  • Anticholinergic Agents: Co-administration with other medicines possessing anticholinergic properties (e.g., tricyclic antidepressants) results in an additive effect, increasing the severity of anticholinergic outcomes.
  • Alcohol and CNS Depressants: Co-administration with alcohol is documented to increase the risk of Central Nervous System (CNS) depression.

Population Note: Official labeling notes that the severity of these anticholinergic interactions is more pronounced in elderly patients.

Mechanism of Action

Swei employs a complementary dual-mechanism to modulate key physiological processes in the digestive tract by affecting two distinct mechanistic systems: existing luminal acidity and autonomic neural control.

Direct Modulation of Gastric pH via Chemical Neutralization

The Aluminum Hydroxide component acts locally by engaging in a rapid chemical neutralization reaction with the free hydrochloric acid ( HCl) in the stomach. This mechanism immediately consumes protons, leading to an elevation of the pH within the gastric lumen. This non-receptor-mediated action establishes a physiological effect of reduced chemical potential due to the change in pH.

Antagonism of Peripheral Cholinergic Signaling

The Homatropine component works via a systemic mechanism of competitive antagonism at peripheral muscarinic cholinergic receptors ( M1, M2, M3) . By blocking the binding of acetylcholine to these receptors on smooth muscle and secretory cells, the mechanism leads to a reduction in neural input from the parasympathetic autonomic system. The mechanism contributes to the physiological consequences of spasmolysis (relaxation of involuntary gastrointestinal muscle tone) and a sustained decrease in cholinergically-driven acid secretion.

Dosage and Administration Information

How Swei is Used in Clinical Practice

The usage of Swei, an antacid-anticholinergic combination, follows established principles for short-term, symptomatic management of digestive discomfort. The medicine is intended for the oral route of administration and is available in both tablet and oral suspension forms. The dosing schedule is primarily structured for as-needed use during acute episodes of discomfort and is not intended for continuous, routine maintenance therapy.

Administration Timing and Preparation

Swei is generally administered after meals and at bedtime to maximize the acid-neutralizing capacity of the antacid component within the stomach. When utilizing the oral suspension, the container must be shaken well prior to use, and the dose should be measured using a calibrated measuring device to ensure precision, as household spoons are unsuitable for accurate administration.

Use Duration and Constraints

Administration of Swei is typically constrained to a short-term duration, generally recommended for no more than two consecutive weeks unless specifically determined by a healthcare provider. A crucial procedural constraint is the requirement to separate Swei administration from other oral medications by a minimum of 2 hours. This instruction prevents the aluminum component from interfering with the absorption of concurrently taken drugs. If a dose is missed, the next dose should be taken at the scheduled time; a double dose must not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Swei

Research has explored this combination in studies involving common digestive symptoms. Because the medicine combines two active ingredients, studies have often been designed to investigate conditions characterized by both acid-related discomfort and muscle spasms, focusing on short-term changes and symptomatic patterns.


Evidence for Symptom Patterns in GI Conditions

The combination was studied for use in the research context of symptoms associated with Peptic Ulcer Disease (PUD) in older, controlled trials. Researchers measured changes in ulcer status and monitored patient-reported pain scores. These findings describe observed symptom change patterns but are generally considered non-definitive, as the research predates modern treatment standards.

For Gastroesophageal Reflux Disease (GERD) and Gastritis, the combination was observed in controlled trials examining patient-reported experiences. Research compared the dual agent with antacid monotherapy. Findings were mixed when assessing whether the anti-spasmodic component contributed to different symptom change patterns compared to antacid alone for global symptom observations. Similar acute-care studies for Concurrent Heartburn and Cramping focused on quick symptomatic changes but often presented mixed or uncertain subgroup findings.


Research Limitations and Gaps

The primary research limitations involve the follow-up durations, which were limited to short-term observation (days or weeks), meaning the long-term effects of this combination are not fully established. Evidence quality varies across studies, with sample sizes being modest in some comparative trials. Furthermore, data for specific patient groups, such as children, adolescents, or pregnant individuals, remain insufficient in the official regulatory record, and the results apply mainly to the adult populations studied.

Key Studies & References

  1. Label: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE syrup (Reference for special population data limitations)

Frequently Asked Questions (FAQ)

Common questions about Swei (FAQ)


Q: What is the main reason a doctor would prescribe Swei?

Official product information indicates that Swei is prescribed for the short-term, symptomatic relief of various digestive discomforts. This includes issues like heartburn, sour stomach, and acid indigestion, especially when these symptoms are accompanied by stomach cramping or spasm.


Q: Is Swei a brand name or the actual drug name?

The official name of the medication is based on its two active components, Aluminum Hydroxide and Homatropine. Regulatory documents list the active ingredients, while 'Swei' would be the brand name used by the pharmaceutical company for this specific combination product.


Q: How quickly does Swei typically start to work?

The Antacid component (Aluminum Hydroxide) is designed to be rapid-acting. Its mechanism involves immediate chemical neutralization of stomach acid, which is associated with a rapid onset of symptom relief.


Q: What happens if I stop taking Swei suddenly?

Since Swei is generally intended for short-term, as-needed relief and not for continuous maintenance therapy, regulatory guidance does not include a specific discontinuation schedule. Official prescribing information for this combination, which is intended for short-term use, does not generally list specific drug-dependency or withdrawal symptoms upon cessation.


Q: Will Swei make me feel tired or drowsy?

The Homatropine component of Swei can cause central nervous system effects, such as dizziness, confusion, or mental clouding. Official warnings advise that patients who experience impaired mental alertness should avoid activities that require concentration, such as driving or operating machinery.


Q: What serious side effects should people know about Swei?

Clinically significant risks are primarily associated with prolonged use of the Aluminum Hydroxide component. These risks include the potential for aluminum accumulation and low phosphate levels (Hypophosphatemia). The risk is heightened in individuals with impaired kidney function and may involve neurological and skeletal toxicity.


Q: Is Swei safe for people with liver problems?

The official eligibility map states that caution is required for patients with severe impairment of liver function. This is because liver problems may affect how the body processes the Homatropine component of the medication.


Q: Are there any common foods or drinks to avoid while taking Swei?

Regulatory documents advise against the consumption of alcohol while using Swei due to the risk of increased central nervous system depression. Additionally, the Antacid component may interact with citrate-containing foods or beverages, such as citrus fruits and juices, requiring a separation of 2 to 3 hours between administration.


Q: Does Swei interact with over-the-counter pain relievers like ibuprofen?

The Antacid component of Swei can affect the absorption of many orally administered medicines, including some over-the-counter pain relievers. To ensure adequate absorption of other medicines, the regulatory label specifies separating the dose of Swei from other oral medications by a minimum of 2 hours.


Q: Is it true that Swei interacts with certain blood pressure medications?

Official interaction profiles indicate that the Antacid component may interfere with the absorption of many oral medicines, including some used for blood pressure, by binding to them in the stomach. Furthermore, the anticholinergic component may influence heart rate, which is relevant for people managing cardiovascular conditions.


Q: Is Swei considered a controlled substance?

No, Swei is a combination of an antacid (Aluminum Hydroxide) and an anticholinergic (Homatropine). Regulatory agencies do not classify it as a controlled substance.


Q: Can people with a history of heart issues take Swei?

Swei is noted to require caution in people with a history of heart conditions. This is because the Homatropine component can increase heart rate, which is documented as tachycardia in the official adverse reaction profile.


Q: Does Swei affect a person's mood or behavior?

Yes, the anticholinergic effects of Swei can affect the central nervous system. Official adverse reaction reporting includes the potential for confusion, disorientation, dizziness, and mood changes.


Q: Why is the maximum recommended dose of Swei important?

The maximum recommended dose is set to minimize the risk of serious side effects. Exceeding the limit increases the chance of aluminum accumulation and low phosphate levels (Hypophosphatemia), particularly if the drug is used for longer than the recommended short-term duration.


Q: Can Swei be taken if a person has diabetes?

Diabetes itself is not listed as a contraindication for Swei. However, due to potential drug interactions, use of Swei requires confirmation with a healthcare provider when taken alongside treatments for diabetes.


Q: Are there any specific warnings about Swei and driving or operating machinery?

Yes, official warnings advise that because Swei can cause side effects such as blurred vision, dizziness, and mental clouding, patients must be cautioned to avoid driving or operating heavy machinery until they know how the medication affects their ability to perform these tasks safely.


Q: Is Swei used for more than one main health problem?

Yes, Swei is a combination product designed to address two coexisting issues in the digestive tract simultaneously. The dual therapeutic action includes quick relief from acid-related symptoms and relief from functional symptoms like painful cramping or spasm.


Q: Can Swei affect sleep patterns?

The anticholinergic component of Swei can cause central nervous system effects, and in some individuals, this may lead to agitation or hyperactivity. This documented effect could potentially disrupt normal sleep patterns.


Q: Why do doctors prescribe Swei instead of an older medicine?

The rationale for prescribing the Swei combination is its dual therapeutic action, which is not provided by an antacid alone. Official information highlights that the medicine offers both quick neutralization of acidity and a reduction in painful cramping or spasm.


Q: Are there different strengths or versions of Swei available?

Official product information confirms that Swei is available in different forms, specifically as a tablet and an oral suspension. The medication may also be supplied in different strengths designed to address varying patient needs.


Q: How is Swei metabolized or processed by the body?

The processing of Swei depends on its two active ingredients. The Aluminum Hydroxide component is minimally absorbed and primarily excreted in the feces, while the Homatropine component is processed systemically and can be affected by liver function.


Q: Is it necessary to have blood tests while taking Swei?

Blood tests may be necessary for some patients, particularly if Swei is used for long periods beyond the short-term recommendation. This monitoring is required to check for changes in phosphate levels (Hypophosphatemia) or aluminum accumulation, which are official risks associated with prolonged use.


Q: Can Swei cause changes to appetite?

Changes such as loss of appetite have been reported as a potential adverse reaction for products containing an anticholinergic component. This effect is thought to be related to the anticholinergic mechanism, which can reduce involuntary gastrointestinal movement.


Q: Does Swei have a withdrawal period if stopped?

As Swei is intended for short-term, symptomatic use, official labeling does not specify a withdrawal period or dependency risk upon cessation.


Q: Can Swei be split or crushed if someone has trouble swallowing pills?

Official guidance advises that unless the tablet form is explicitly designated as chewable or designed to be altered, it should be swallowed whole. Crushing or splitting tablets may interfere with how the medication is intended to work, and the oral suspension form is available as an alternative for those with difficulty swallowing.


Q: Why is Swei not available without a prescription?

Swei is a prescription-only medication because it contains Homatropine, which is classified as an anticholinergic agent. Due to this component's potential side effects and specific contraindications (such as narrow-angle glaucoma), its use requires professional supervision.

How should Swei be stored and disposed of?

How to Store and Dispose of Swei?

The official labeling requires Swei to be stored under controlled conditions to maintain its quality and efficacy.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature (typically 15°C to 30°C or 59°F to 86°F).
Protection Store in the original container and keep it tightly closed. The product must be protected from excess moisture, heat, and direct sunlight.
Prohibited Do not freeze this medication, especially the oral suspension form.
Safety Keep out of the sight and reach of children and pets at all times.

Disposal Instructions

To dispose of unused or expired Swei, the primary regulatory recommendation is to use an authorized Drug Take-Back Program or a pharmaceutical mail-back service. If a take-back option is unavailable, the product may be placed in the household trash after mixing it with an undesirable substance, such as dirt or used coffee grounds, and sealing it in a container. Do not empty into drains or flush into wastewater systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Swei found in:

A-Z Index: